OncoMatch/Clinical Trials/NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
Is NCT06242470 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including MGC026 Dose Escalation and MGC026 Dose for Expansion for advanced solid tumor.
Treatment: MGC026 Dose Escalation · MGC026 Dose for Expansion — The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Urothelial Carcinoma
Sarcoma
Endometrial Cancer
Melanoma
Prostate Cancer
Cervical Cancer
Colorectal Cancer
Gastric Cancer
Esophageal Carcinoma
Pancreatic Cancer
Renal Cell Carcinoma
Hepatocellular Carcinoma
Ovarian Cancer
Breast Carcinoma
Prior therapy
Cannot have received: B7-H3 targeted agent
Prior treatment with any B7-H3 targeted agent for cancer
Cannot have received: antibody-drug conjugate
Exception: ADC with a topoisomerase payload
any ADC with a topoisomerase payload
Cannot have received: autologous or allogeneic stem cell or solid organ transplant
Prior autologous or allogeneic stem cell or solid organ transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute · Los Angeles, California
- START Midwest · Grand Rapids, Michigan
- START-New York Long Island · Lake Success, New York
- Providence Cancer Institute · Portland, Oregon
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06242470 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3 targeted agent, antibody-drug conjugate, autologous or allogeneic stem cell or solid organ transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify